SCHEMBL3445368

SCHEMBL3445368

CCC(CO)Nc1nc(Nc2ccc(Cl)c(N)c2)c2c(n1)N(C(C)C)NN2C(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 12/20 0.45
CDK5R1 Q15078 10/20 0.45
KDM4E B2RXH2 2/20 0.45
MAPT P10636 2/20 0.45
NPC1 O15118 1/20 0.45
POLB P06746 1/20 0.45
CDK2 P24941 12/20 0.40
CCNA2 P20248 10/20 0.40
CCNA1 P78396 9/20 0.40
DYRK1A Q13627 8/20 0.40
CCNK O75909 1/20 0.39
CDK12 Q9NYV4 1/20 0.39
CCNE1 P24864 3/20 0.39
CDK1 P06493 5/20 0.38
CSNK1A1 P48729 2/20 0.38
CCNT1 O60563 1/20 0.38
CCNB1 P14635 1/20 0.38
CDK7 P50613 1/20 0.38
CDK9 P50750 1/20 0.38
CCNH P51946 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3444005 0.93 CDK5 (0.45) CDK5CDK5R1KDM4EMAPTNPC1
SCHEMBL3445562 0.88 CDK5 (0.47) CDK5CDK5R1KDM4EMAPTCDK2
SCHEMBL3444864 0.87 CDK5 (0.47) CDK5CDK5R1KDM4EMAPTNPC1
SCHEMBL3444683 0.86 CDK2 (0.47) CDK5CDK5R1CDK2CCNA2CCNA1
SCHEMBL3445302 0.85 CDK1 (0.47) CDK5CDK5R1KDM4EMAPTNPC1
SCHEMBL3444962 0.85 CDK5 (0.61) CDK5CDK5R1KDM4EMAPTNPC1
SCHEMBL3444672 0.85 CDK5 (0.50) CDK5CDK5R1KDM4EMAPTNPC1
SCHEMBL3444436 0.83 CDK2 (0.46) CDK5CDK5R1KDM4EMAPTNPC1
SCHEMBL3445478 0.83 KCNH3 (0.53) CDK5CDK5R1KDM4EMAPTNPC1
SCHEMBL3444854 0.81 BCDIN3D (0.40) CDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060035909-A1 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2006-02-16 US claimed
US-7816350-B2 Substituted [1,2,3] triazolo[4,5-D]pyrimidines as cdk inhibitors INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) 2010-10-19 US disclosed
US-20060035909-A1 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2006-02-16 US disclosed
EP-1539760-A2 AZAPURINE DERIVATIVES INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) 2005-06-15 EP disclosed
WO-2004018473-A2 AZAPURINE DERIVATIVES INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035909-A1 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout CDK8, CDK6, CDK1 CDK5 9/4885CDK5R1 20/4885KDM4E 329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.